Todd A V, Ireland C M, Iland H J
Kanematsu Laboratories, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Leukemia. 1991 Feb;5(2):160-1.
Point mutations involving codons 12, 13, and 61 of the N-ras gene are found in patients with acute myeloid leukemia (AML). We have developed a sensitive assay for the analysis of these mutations which we have called allele-specific enrichment. In this protocol the polymerase chain reaction (PCR) amplifies DNA with primers that introduce new restriction sites into the normal N-ras allele only. Digestion with the appropriate enzyme cleaves normal, but not mutant, alleles and this digested product provides a mutant allele-enriched template for a second round of amplification. The second PCR product is digested, Southern blotted and analyzed by allele-specific oligonucleotide (ASO) hybridization. This protocol is more sensitive than ASO hybridization alone and has revealed a minor clone in the DNA of a patient with AML. The method may be useful for the detection of minimal residual disease in a subset of patients in remission.
在急性髓系白血病(AML)患者中发现了涉及N-ras基因第12、13和61密码子的点突变。我们开发了一种用于分析这些突变的灵敏检测方法,称为等位基因特异性富集。在此方案中,聚合酶链反应(PCR)使用仅在正常N-ras等位基因中引入新限制性位点的引物扩增DNA。用适当的酶消化可切割正常等位基因而非突变等位基因,这种消化产物为第二轮扩增提供了富含突变等位基因的模板。第二个PCR产物经消化、Southern印迹,并通过等位基因特异性寡核苷酸(ASO)杂交进行分析。该方案比单独的ASO杂交更灵敏,并在一名AML患者的DNA中检测到一个小克隆。该方法可能有助于检测部分缓解期患者的微小残留病。